DE2555609A1 - Pharmazeutisches praeparat zur therapie der hyperurikaemie - Google Patents
Pharmazeutisches praeparat zur therapie der hyperurikaemieInfo
- Publication number
- DE2555609A1 DE2555609A1 DE19752555609 DE2555609A DE2555609A1 DE 2555609 A1 DE2555609 A1 DE 2555609A1 DE 19752555609 DE19752555609 DE 19752555609 DE 2555609 A DE2555609 A DE 2555609A DE 2555609 A1 DE2555609 A1 DE 2555609A1
- Authority
- DE
- Germany
- Prior art keywords
- allopurinol
- therapy
- benzbromarone
- uric acid
- pharmaceutical preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001431 Hyperuricemia Diseases 0.000 title claims description 7
- 238000002560 therapeutic procedure Methods 0.000 title claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims description 28
- 229960003459 allopurinol Drugs 0.000 claims description 28
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 claims description 22
- 229960002529 benzbromarone Drugs 0.000 claims description 22
- 239000004480 active ingredient Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 15
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 15
- 229940116269 uric acid Drugs 0.000 description 15
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 230000029142 excretion Effects 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 5
- 238000012153 long-term therapy Methods 0.000 description 5
- HXNFUBHNUDHIGC-UHFFFAOYSA-N oxypurinol Chemical compound O=C1NC(=O)N=C2NNC=C21 HXNFUBHNUDHIGC-UHFFFAOYSA-N 0.000 description 5
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 239000004359 castor oil Substances 0.000 description 4
- 235000019438 castor oil Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 230000003347 uricostatic effect Effects 0.000 description 3
- 230000003424 uricosuric effect Effects 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229920000945 Amylopectin Polymers 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229940116731 Uricosuric agent Drugs 0.000 description 2
- 108010093894 Xanthine oxidase Proteins 0.000 description 2
- 102100033220 Xanthine oxidase Human genes 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003979 granulating agent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229950002752 oxipurinol Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- KJHYAEZMOHLVCH-UHFFFAOYSA-N 2-ethyl-1-benzofuran Chemical compound C1=CC=C2OC(CC)=CC2=C1 KJHYAEZMOHLVCH-UHFFFAOYSA-N 0.000 description 1
- PQGCEDQWHSBAJP-TXICZTDVSA-N 5-O-phosphono-alpha-D-ribofuranosyl diphosphate Chemical compound O[C@H]1[C@@H](O)[C@@H](O[P@](O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O PQGCEDQWHSBAJP-TXICZTDVSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 description 1
- 108700016257 Tryptophan 2,3-dioxygenases Proteins 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000011340 continuous therapy Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19752555609 DE2555609A1 (de) | 1975-12-10 | 1975-12-10 | Pharmazeutisches praeparat zur therapie der hyperurikaemie |
| GB19223/76A GB1493237A (en) | 1975-12-10 | 1976-05-11 | Pharmaceutical preparations for the treatment of hyperuricacidemia |
| NL7605531A NL7605531A (nl) | 1975-12-10 | 1976-05-24 | Gedoseerd farmaceutisch preparaat voor de therapie van hyperurikaemie. |
| ZA763081A ZA763081B (en) | 1975-12-10 | 1976-05-24 | Pharmaceutical preparations for the treatment of hyperuricacidemia |
| CA76253650A CA1048933A (en) | 1975-12-10 | 1976-05-28 | Pharmaceutical preparations for the treatment of hyperuricacidemia |
| BE167474A BE842389A (fr) | 1975-12-10 | 1976-05-31 | Composition pharmaceutique pour le traitement de l'hyperuricemie |
| FR7616454A FR2334362A1 (fr) | 1975-12-10 | 1976-06-01 | Composition pharmaceutique pour le traitement de l'hyperuricemie |
| AU15413/76A AU505476B2 (en) | 1975-12-10 | 1976-06-29 | Pharmaceutical composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19752555609 DE2555609A1 (de) | 1975-12-10 | 1975-12-10 | Pharmazeutisches praeparat zur therapie der hyperurikaemie |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2555609A1 true DE2555609A1 (de) | 1977-06-30 |
Family
ID=5964014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752555609 Pending DE2555609A1 (de) | 1975-12-10 | 1975-12-10 | Pharmazeutisches praeparat zur therapie der hyperurikaemie |
Country Status (8)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1698348A4 (en) * | 2003-11-14 | 2008-02-27 | Human Cell Systems Inc | CURATIVE OR PREVENTIVE REMEDY FOR VASCULAR DISORDERS AND HYPERTENSION AND SCREENING METHOD THEREOF |
| EP1721890A4 (en) | 2004-03-01 | 2008-02-27 | Japan Science & Tech Agency | PROCESS FOR THE ALLYLATION OF N-ACYLHYDRAZONES |
| EP1778261A4 (en) * | 2004-07-21 | 2010-08-11 | Univ Florida | COMPOSITIONS AND METHODS FOR TREATMENT AND DIAGNOSIS OF INSULIN RESISTANCE |
| JP5844376B2 (ja) * | 2010-10-06 | 2016-01-13 | ジェイファーマ株式会社 | 強力な尿酸トランスポーター阻害剤の開発：それらの尿酸排泄効果のために設計された化合物 |
| CN103242272B (zh) * | 2013-05-22 | 2016-01-27 | 合肥医工医药有限公司 | 一种制备苯溴马隆的方法 |
-
1975
- 1975-12-10 DE DE19752555609 patent/DE2555609A1/de active Pending
-
1976
- 1976-05-11 GB GB19223/76A patent/GB1493237A/en not_active Expired
- 1976-05-24 ZA ZA763081A patent/ZA763081B/xx unknown
- 1976-05-24 NL NL7605531A patent/NL7605531A/xx not_active Application Discontinuation
- 1976-05-28 CA CA76253650A patent/CA1048933A/en not_active Expired
- 1976-05-31 BE BE167474A patent/BE842389A/xx not_active IP Right Cessation
- 1976-06-01 FR FR7616454A patent/FR2334362A1/fr active Granted
- 1976-06-29 AU AU15413/76A patent/AU505476B2/en not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| AU1541376A (en) | 1978-01-05 |
| BE842389A (fr) | 1976-09-16 |
| FR2334362B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1979-08-24 |
| ZA763081B (en) | 1977-04-27 |
| NL7605531A (nl) | 1977-06-14 |
| CA1048933A (en) | 1979-02-20 |
| FR2334362A1 (fr) | 1977-07-08 |
| GB1493237A (en) | 1977-11-30 |
| AU505476B2 (en) | 1979-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2813480C2 (de) | Arzneimittel-Depotpräparat vom Mehrfacheinheitsdosen-Typ | |
| DE2224534C3 (de) | Pharmazeutisches Präparat mit langsamer Wirkstoffabgabe | |
| DE19541128C2 (de) | Stabilisierte schilddrüsenhormonhaltige Arzneimittel | |
| DE69128760T2 (de) | Antidiarrhoeika | |
| EP0150792B1 (de) | Arzneimittel und die Verwendung schwerlöslicher Calcium- und/oder Magnesiumverbindungen zur Herstellung eines Arzneimittels | |
| DE2520978C3 (de) | Dosierungseinheit einer festen, oral zu verabreichenden Arzneiform von wasserlöslichen Xanthin-Derivaten | |
| DE68915269T2 (de) | Polyvalentes entzündungshemmendes mittel. | |
| DE2446058A1 (de) | Galenische zubereitung fuer die allopurinol-dauertherapie | |
| EP0146863A2 (de) | Orale retardierte Acetylsalicylsäureformulierungen | |
| DE2555609A1 (de) | Pharmazeutisches praeparat zur therapie der hyperurikaemie | |
| EP0117274B1 (de) | Kaliumneutrales Saluretikum mit antihypertensiver Wirkung | |
| DE19726871C1 (de) | Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe | |
| DE1617336C2 (de) | Arzneimittel gegen Angina pectoris | |
| DE3904795C2 (de) | Pharmazeutisches Präparat und dessen Verwendung | |
| DE2157201C3 (de) | Verbesserte feste orale Applikationsform von Raubasin | |
| DE60312642T2 (de) | Pharmazeutische zusammensetzung mit modifizierter freisetzung | |
| DE3730957C2 (de) | Lösliches Thiamphenicol-Präparat | |
| DE69103724T2 (de) | Pharmazeutische zusammensetzungen mit verzögerter freisetzung zur oralen verabreichung sowie deren herstellungsverfahren. | |
| DE3930282A1 (de) | Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit | |
| DE1964504A1 (de) | Arzneimittelzubereitung mit einem Gehalt an 3-Butylamino-4-phenoxy-5-sulfamyl-benzoesaeure und deren Salzen | |
| DE3511236C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| DE69030237T2 (de) | Kalispenderzubereitung | |
| DE2743702A1 (de) | Abmagerungs- oder schlankmacher- zubereitung und verfahren zu ihrer herstellung | |
| DE69936773T2 (de) | Behandlung von depression und zusammensetzungen dazu | |
| DE69103294T2 (de) | Verwendung der 3-Oxygermylpropionsäure zur Behandlung und Prävention von Diabetes verursacht durch Autoimmunkrankheiten. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| OHW | Rejection |